These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12669118)

  • 21. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.
    Lee IH; Chung SI; Lee SY
    Exp Mol Med; 2002 Nov; 34(5):385-90. PubMed ID: 12526104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
    Duval C; Ali M; Chaudhry WW; Ridger VC; Ariëns RA; Philippou H
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):308-16. PubMed ID: 26743168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protease-activated receptor 4-like peptides bind to thrombin through an optimized interaction with the enzyme active site surface.
    Cleary DB; Trumbo TA; Maurer MC
    Arch Biochem Biophys; 2002 Jul; 403(2):179-88. PubMed ID: 12139967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII.
    Naski MC; Lorand L; Shafer JA
    Biochemistry; 1991 Jan; 30(4):934-41. PubMed ID: 1989686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody.
    Lukacova D; Matsueda GR; Haber E; Reed GL
    Biochemistry; 1991 Oct; 30(42):10164-70. PubMed ID: 1681898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the roles of thrombin and calcium in the activation of coagulation factor XIII using H/D exchange and MALDI-TOF MS.
    Turner BT; Maurer MC
    Biochemistry; 2002 Jun; 41(25):7947-54. PubMed ID: 12069584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proline 36 of the Factor XIII Activation Peptide Plays a Crucial Role in Substrate Recognition and Zymogen Activation.
    Li B; Billur R; Maurer MC; Kohler HP; Raddatz Müller P; Alberio L; Schroeder V
    Thromb Haemost; 2018 Dec; 118(12):2037-2045. PubMed ID: 30419598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping of factor XIII solvent accessibility as a function of activation state using chemical modification methods.
    Turner BT; Sabo TM; Wilding D; Maurer MC
    Biochemistry; 2004 Aug; 43(30):9755-65. PubMed ID: 15274630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational analysis of gamma' peptide (410-427) interactions with thrombin anion binding exosite II.
    Sabo TM; Farrell DH; Maurer MC
    Biochemistry; 2006 Jun; 45(24):7434-45. PubMed ID: 16768439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the reciprocal binding sites on human alpha-thrombin and factor XIII A-chain.
    Achyuthan KE
    Mol Cell Biochem; 1998 Jan; 178(1-2):289-97. PubMed ID: 9546612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate.
    Philippou H; Rance J; Myles T; Hall SW; Ariens RA; Grant PJ; Leung L; Lane DA
    J Biol Chem; 2003 Aug; 278(34):32020-6. PubMed ID: 12794066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural resiliency of an EGF-like subdomain bound to its target protein, thrombin.
    Hrabal R; Komives EA; Ni F
    Protein Sci; 1996 Feb; 5(2):195-203. PubMed ID: 8745396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form.
    Schroeder V; Vuissoz JM; Caflisch A; Kohler HP
    Thromb Haemost; 2007 Jun; 97(6):890-8. PubMed ID: 17549290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activation of factor XIII by beta-thrombin].
    Umarova BA; Strukova SM
    Biokhimiia; 1979 Aug; 44(8):1524-9. PubMed ID: 497297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
    Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
    Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin.
    Takagi T; Doolittle RF
    Biochemistry; 1974 Feb; 13(4):750-6. PubMed ID: 4811064
    [No Abstract]   [Full Text] [Related]  

  • 37. Perturbations in factor XIII resulting from activation and inhibition examined by solution based methods and detected by MALDI-TOF MS.
    Sabo TM; Brasher PB; Maurer MC
    Biochemistry; 2007 Sep; 46(35):10089-101. PubMed ID: 17691819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombin hydrolysis of an N-terminal peptide from fibrinogen Lille: kinetic and NMR studies.
    Zheng Z; Ashton RW; Ni F; Scheraga HA
    Biochemistry; 1992 May; 31(18):4426-31. PubMed ID: 1581297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.
    De Cristofaro R; De Filippis V
    Biochem J; 2003 Jul; 373(Pt 2):593-601. PubMed ID: 12689334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions.
    Nielsen VG
    Acta Anaesthesiol Scand; 2005 Sep; 49(8):1163-71. PubMed ID: 16095459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.